NDC-0524 Shows Promise in Targeting Toxic Protein Clumps in Parkinson’s Disease

A new experimental treatment from Nitrase Therapeutics is showing promise in early research for Parkinson’s disease. The treatment, called NDC-0524, is a lab-made antibody designed to find and block a harmful form of a protein called alpha-synuclein. In Parkinson’s, this protein can build up into toxic clumps in the brain and damage the nerve cells that help control movement. How the Treatment Works The antibody targets a specific version of alpha-synuclein known as nitrated alpha-synuclein, which is more likely to form these toxic clumps. In several studies using models of Parkinson’s, NDC-0524 helped reduce the amount of these clumps by up to 88%, potentially slowing the spread of damage in the brain. It also appeared to work better than a similar treatment currently in development, although more testing is needed to confirm this. What’s Next? A first clinical trial in humans is planned for later this year. It will include both people with Parkinson’s and healthy volunteers. Researchers will look at whether the treatment is safe, how the body responds to it, and whether it reaches the right targets in the brain. Looking to the Future In addition to this antibody, the company is also developing other treatments that may help prevent harmful protein clumps from forming in the first place. While this research is still in the early stages, it offers hope for slowing disease progression and improving quality of life for people living with Parkinson’s.